Contribution of Leukocyte Platelet Aggregates to Development of Thrombosis in Patients With Advanced Cancer
Abstract
Aim:
To determine the relations between
leukocyte platelet aggregates and thrombosis in patients with solid
tumors who are susceptible to inflammation and thrombosis. Method: Laboratory
and clinical data of 28 metastatic gastrointestinal tumors, 33 metastatic lung
tumors, 29 operated tumor patients, were compared with a control group
consisting of 12 healthy controls . Monocyte platelet aggregates, granulocyte
platelet aggregates; thrombin-antithrombin III complex and high-sensitivity
C-reactive protein levels were studied. The formation of deep vein thrombosis
(DVT) was prospectively evaluated in patients. Results: Monocyte platelet
aggregate levels of metastatic gastrointestinal tumors and operated tumors were
found to be significantly higher compared to the control group (p: 0.05, 0.029,
respectively). Granulocyte platelet aggregates level in all of the tumors of
metastatic gastrointestinal, metastatic lung and operated tumors were found to
be significantly higher compared with the control group (p = 0.015; 0,0,012;
0.01, respectively). No significant difference was observed between the groups
in the levels of thrombin-antithrombin III complex and neutrophil lymphocyte
ratio. The incidence of DVT was identified as
22% (18 patients). Conclusion: The increase in levels of leukocyte
platelet aggregate values increases in cancer patients of different stages and
different tissue origin. To confirm the results we have achieved, and to
demonstrate the potential impact of this information in estimation of
thrombotic events in cancer patients more studies conducted in larger groups of
patients are needed.
Keywords
References
- Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007 Apr;5(4):692-9.
- 2. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007 Jul 23;167(14):1471-5.
- 3. Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, Sørensen HT. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. Sep 28;103(7):947-53.
- 4. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809-15.
- 5. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003;9(6):263-258
- 6. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand. 2001;173(1):35-43.
- 7. Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 2004;14(1):18-22.
- 8. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy; risk analysis using Medicare claims data. Medicine.(Baltimore) 1999;78:285-291
- 9. Siegfried JM. Biology and chemoprevention of lung cancer. Chest 1999;113 Supp l:40-5.
- 10. Turgut B, Turgut N, Celik Y, Tekgündüz E, Pamuk GE, Demir MDifferences in platelet–leukocyte aggregates among subtypes of acute cerebral ischemia. Journal of the Neurological Sciences 305 (2011) 126–130
- 11. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. September 5, 2013; Blood: 122 (10)
Abstract
Giriş:
Çalışmamızın amacı inflamasyon ve tromboza yatkınlıkla giden solid organ tümörü
hastalarinda lökosit trombosit agregatlari ve tromboz ilişkisini tespit
etmektir. Metod: Çalışmada Namık Kemal Üniversitesi Onkoloji Bilim Dalı’ nda 2013 -2014 tarihleri
arasında izlenen 28 metastatik GİS tümörü, 33 metastatik akciğer tümörü, 29
opere tümör olgusu olmak üzere toplam 90 hastaya ilişkin labaratuar ve klinik
verileri 12 sağlıklı gönüllüden oluşan
kontrol grubu ile karşilaştırıldı. Monosit trombosit agregatları, granülosit
trombosit agregatları; trombin- antitrombin III kompleks ve C reaktif protein
düzeyleri çalışıldı. Mevcut verilerden nötrofil lökosit oranı hesap edildi.
Hastalarda venöz tromboz tespiti için ise
derin ven trombozu (DVT) prospektif olarak değerlendirildi. Bulgular :
Çalışmamızda monosit trombosit agregatları düzeyi metastatik GİS tümörlerinde
ve opere tümörlerde kontrol gruba göre anlamlı düzeyde yüksek tespit edildi
(p:0,05;0,029 sırasıyla). Granülosit trombosit agregatları düzeyi ise
metastatik GİS, metastatik akciğer ve opere tümörlerin tümünde kontrol gruba
göre anlamlı düzeyde yüksek saptandı (p:0,015;0,012;0,01 sırasıyla).
Hiperkoagülopatinin değerlendirilmesine yönelik tüm gruplar analiz edildiğinde
DVT sıklığı %22 (18 hasta) olarak tespit edildi. DVT olanlar ile olmayanlar arasında yaş,
monosit trombosit agregatları, granülosit trombosit agregatları, trombin-
antitrombin III kompleks ve yüksek duyarlıklı C reaktif protein değerleri
arasında fark saptanmadı. Sonuç:
Literatürde ilk kez farklı farklı evre ve farklı dokulardan kaynaklı kanser
hastalarında lökosit trombosit agregatı değerlerinin normal kontrollere göre
daha yüksek olduğunu tespit ettik. Elde ettiğimiz sonuçları doğrulamak ve bu
bilgilerin kanser hastalarında trombotik olayların tahmininde potansiyel
etkisini ortaya koymak için daha büyük hasta grupları ile yapılan çalışmalara
ihtiyaç vardır.
Keywords
References
- Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007 Apr;5(4):692-9.
- 2. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007 Jul 23;167(14):1471-5.
- 3. Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, Sørensen HT. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. Sep 28;103(7):947-53.
- 4. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809-15.
- 5. Ley K. The role of selectins in inflammation and disease. Trends Mol Med 2003;9(6):263-258
- 6. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand. 2001;173(1):35-43.
- 7. Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 2004;14(1):18-22.
- 8. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy; risk analysis using Medicare claims data. Medicine.(Baltimore) 1999;78:285-291
- 9. Siegfried JM. Biology and chemoprevention of lung cancer. Chest 1999;113 Supp l:40-5.
- 10. Turgut B, Turgut N, Celik Y, Tekgündüz E, Pamuk GE, Demir MDifferences in platelet–leukocyte aggregates among subtypes of acute cerebral ischemia. Journal of the Neurological Sciences 305 (2011) 126–130
- 11. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. September 5, 2013; Blood: 122 (10)
Details
| Journal Section | Orginal Article |
|---|---|
| Authors | |
| Publication Date | April 12, 2017 |
| Published in Issue | Year 2017 Volume: 5 Issue: 1 |